Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.21.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]            
Total revenue   $ 3,285   $ 11,246 $ 18,918 $ 24,507
Seagen            
Disaggregation of Revenue [Line Items]            
Total revenue   338   8,512 704 8,960
AstraZeneca            
Disaggregation of Revenue [Line Items]            
Total revenue $ 13,000 2,202 $ 13,000 2,334 16,702 5,045
Servier            
Disaggregation of Revenue [Line Items]            
Total revenue   $ 745   $ 400 $ 1,512 $ 10,502